

ADDITIONAL INVESTMENT IN DIGITAL LIFE LINE PTE. LTD.

1. INTRODUCTION

The Board of Directors (the "**Board**" or "**Directors**") of DISA Limited (the "**Company**" and together with its subsidiaries, the "**Group**") wishes to announce that the Company has on 2 December 2024, through its wholly-owned subsidiary, Disa Digital Safety Pte. Ltd. ("**DiSa**"), increased its investment in the share capital of Digital Life Line Pte. Ltd. ("**DLL**") by subscribing for an additional 186,963,256 new ordinary shares in DLL ("**DLL Shares**") in cash at S\$0.00118545 per DLL Share for a total subscription amount of S\$221,638 through a rights issue exercise carried out by DLL (the "**Proposed Additional Investment**").

Following the Proposed Additional Investment, DiSa's total investment in DLL increased from S\$1,351,656 to S\$1,573,294, with percentage of shareholding remain unchanged at 55.41%.

The Proposed Additional Investment was funded by the internal resources of the Group.

2. INFORMATION ON DLL

Incorporated in 2021, DLL is a Singapore-based ISO13485-certified medical technology company that provides digital, AI-powered diagnostic ophthalmology solutions to enable community-based vision screening for early detection and treatment of vision impairment.

On the date of this announcement, DLL has completed the renounceable rights issue exercise and successfully raised S\$400,000 for additional working capital purposes. Each existing shareholder of DLL is entitled to two (2) rights for each existing DLL Share held at an issue price of S\$0.00118545 per DLL Share. The issue price was determined at a discount of around 8% to DLL's net tangible assets per share as of 31 July 2024, based on the latest available management accounts prior to the rights issue being proposed to the Board of Directors of DLL in August 2024. The Group has participated in the rights issue exercise which resulted in the Proposed Additional Investment.

The shareholding structure in DLL before and after the Proposed Additional Investment are set out below:

	Before the Proposed Additional Investment	After the Proposed Additional Investment
DiSa	55.41%	55.41%
Mr. Chng Weng Wah ⁽¹⁾	4.85%	23.65%
Other individual and institutional investors ⁽²⁾	39.74%	20.94%
Total	100.00%	100.00%

Notes:

(2) None of the other individual and institutional investors is a director or controlling shareholder (as defined in the Catalist Rules) of the Company or their respective associates.

⁽¹⁾ Mr. Chng Weng Wah is the Managing Director and Chief Executive Officer of the Company. He is also a substantial shareholder of the Company with total direct and deemed shareholding of 14.49% in the Company as at the date of this announcement.

3. RATIONALE OF THE PROPOSED ADDITIONAL INVESTMENT

The Board is of the view that the Proposed Additional Investment is in the best interests of the Company as the issue price is reasonably attractive and maintain the Group's control over DLL to facilitate its participation in DLL's ongoing and future projects with potential upside in the future upon successful commercialisation of DLL's products. This strategic expansion via DLL into healthcare segment would also help in broadening the revenue streams of the Group. This is in line with the Group's aims to deliver sustainable returns for the shareholders as the Group sees business potential in DLL.

4. INTEREST OF DIRECTORS AND CONTROLLING SHAREHOLDERS

Save as disclosed in this announcement, none of the Directors or controlling shareholders of the Company has any interest, direct or indirect, in the Proposed Additional Investment other than through their respective shareholdings (if any) in the Company.

5. DIRECTORS' RESPONSIBILITY STATEMENT

The Directors collectively and individually accept full responsibility for the accuracy of the information given in this announcement and confirm after making all reasonable enquiries that, to the best of their knowledge and belief, this announcement constitutes full and true disclosure of all material facts about the Proposed Additional Investment, the Company and its subsidiaries, and the Directors are not aware of any facts the omission of which would make any statement in this announcement misleading. Where information in this announcement has been extracted from published or otherwise publicly available sources or obtained from a named source, the sole responsibility of the Directors has been to ensure that such information has been accurately and correctly extracted from those sources and/or reproduced in this announcement in its proper form and context.

BY ORDER OF THE BOARD

Chng Weng Wah Managing Director and Chief Executive Officer 2 December 2024

This announcement has been reviewed by the Company's sponsor, SAC Capital Private Limited (the "**Sponsor**"). This announcement has not been examined or approved by the Singapore Exchange Securities Trading Limited (the "**SGX-ST**") and the SGX-ST assumes no responsibility for the contents of this announcement including the correctness of any of the statements or opinions made or reports contained in this announcement.

The contact person for the Sponsor is Ms. Lee Khai Yinn (Registered Professional, SAC Capital Private Limited) Address: 1 Robinson Road, #21-01 AIA Tower, Singapore 048542.

Telephone number: +65 6232 3210